All Stories

  1. Rethinking HIV antibody testing in children aged 18-24 months in the OPPTIM study conducted in Johannesburg, South Africa 2018-2021
  2. Health system and household costs of preventive treatment delivery for children exposed to multidrug-resistant tuberculosis in South Africa
  3. Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s
  4. Clot twist – D-dimer analysis of healthy adults receiving heterologous or homologous booster COVID-19 vaccine after a single prime dose of Ad26.COV2.S in a phase II randomised open-label trial, BaSiS
  5. Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial
  6. Factors Predictive of Early Discontinuation of Preventive Treatment in Children With Household Exposure to Multidrug-resistant Tuberculosis
  7. Characterizing the HIV care continuum among children and adolescents with HIV in eastern and southern Africa in the era of “Universal Test and Treat”: A systematic review and meta‐analysis
  8. Bone Mineral Content, Growth, and Renal Health of Infants With Perinatal Exposure to Maternal Dolutegravir Versus Efavirenz and Tenofovir Disoproxil Fumarate Versus Tenofovir Alafenamide: The Randomized IMPAACT 2010 (VESTED) Trial
  9. Risk of tuberculosis infection in young children exposed to multidrug-resistant tuberculosis in the TB-CHAMP multi-site randomised controlled trial
  10. BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection
  11. Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s
  12. Acceptability of a 250 mg levofloxacin formulation in children receiving TB preventive treatment
  13. Vaccine Utilization and Timing of Administration in Pregnant Women: A South African Perspective
  14. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis
  15. The need to avert emergent resistance to dolutegravir in children and adolescents with HIV
  16. Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial
  17. A Meta-Analysis of Levofloxacin for Contacts of Multidrug-Resistant Tuberculosis
  18. Burden of Lassa fever disease in pregnant women and children and options for prevention
  19. Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis
  20. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M TM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 i...
  21. Measles–Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations
  22. South African Parents’ and Grandparents’ Perspectives on the Acceptability of Implant Delivery of Treatment to Young Children with HIV
  23. Brief Report: Subsequent Pregnancies in the IMPAACT 2010/VESTED Trial: High Rate of Adverse Outcomes in Women Living With HIV
  24. Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial
  25. Brief Report: Characterizing HIV Drug Resistance in Cases of Vertical Transmission in the VESTED Randomized Antiretroviral Treatment Trial
  26. Acceptability of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) during Pregnancy in Malawi, South Africa, Uganda, and Zimbabwe
  27. Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants
  28. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
  29. Assessment of weight gain in adult patients living with HIV receiving first‐line dolutegravir‐based or efavirenz‐based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study
  30. Effects of preterm birth, maternal ART and breastfeeding on 24-month infant HIV-free survival in a randomized trial
  31. Clot Twist – D-dimer analysis of healthy adults receiving heterologous or homologous booster COVID-19 vaccine after a single prime dose of Ad26.COV2.S in a phase II randomised open-label trial, BaSiS
  32. Obstetric and neonatal outcomes in South Africa
  33. Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens
  34. Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate–Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum
  35. DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy
  36. More Frequent HIV Viral Load Testing With Point-Of-Care Tests Detects Elevated Viral Load Earlier in Postpartum HIV-Positive Women in a Randomized Controlled Trial in Two Clinics in Johannesburg, South Africa
  37. Translating the consent form is the tip of the iceberg: using cognitive interviews to assess the barriers to informed consent in South African health facilities
  38. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
  39. Preferences for onward health data use in the electronic age among maternity patients and providers in South Africa: a qualitative study
  40. Acceptability of the Dapivirine Vaginal Ring and Oral Truvada Among African Users in Late-Stage of Pregnancy
  41. Safety surveillance for PrEP in pregnant and breastfeeding women
  42. Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents
  43. Potential for Maternally Administered Vaccine for Infant Group B Streptococcus
  44. The burden, prevention and care of infants and children with congenital anomalies in sub-Saharan Africa: A scoping review
  45. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
  46. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial
  47. Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005)
  48. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial
  49. Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19
  50. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
  51. High prevalence of SARS-CoV-2 antibodies in pregnant women after the second wave of infections in the inner-city of Johannesburg, Gauteng Province, South Africa
  52. Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages
  53. T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa
  54. Acceptability of Implants for HIV Treatment in Young Children: Perspectives of Health Care Providers in Johannesburg, South Africa
  55. Ambient temperature during pregnancy and risk of maternal hypertensive disorders: A time-to-event study in Johannesburg, South Africa
  56. Antiretroviral choice and severe disease predict poorer neuropsychological outcomes in HIV+ children from Africa
  57. HIV treatment success in children and adolescents with HIV
  58. SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021
  59. Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial
  60. Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of Concern
  61. Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages
  62. Approaches to accelerating the study of new antiretrovirals in pregnancy
  63. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial
  64. SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021
  65. Combination HIV prevention reduces orphanhood in Uganda
  66. A public health approach to drug use crucial to ending AIDS
  67. Global SARS-CoV-2 seroprevalence: a systematic review and meta-analysis of standardized population-based studies from Jan 2020-May 2022
  68. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir ...
  69. Pooled Prevalence of Adverse Pregnancy and Neonatal Outcomes in Malawi, South Africa, Uganda, and Zimbabwe: Results From a Systematic Review and Meta-Analyses to Inform Trials of Novel HIV Prevention Interventions During Pregnancy
  70. Challenges in recruiting children to a multidrug-resistant TB prevention trial
  71. Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial
  72. Ethically designing research to inform multidimensional, rapidly evolving policy decisions: Lessons learned from the PROMISE HIV Perinatal Prevention Trial
  73. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
  74. Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial
  75. Effects of preconception antiretroviral therapy in placenta development and pregnancy outcomes
  76. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
  77. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
  78. Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age
  79. Brief Report: Impact of ART on Maternal Health After Cessation of Breastfeeding
  80. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAAC...
  81. Assessing pregnancy and neonatal outcomes in Malawi, South Africa, Uganda, and Zimbabwe: Results from a systematic chart review
  82. ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIV
  83. Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
  84. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
  85. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa
  86. Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa
  87. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
  88. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
  89. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3...
  90. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial
  91. Pregnancy Outcomes of Women Conceiving on Antiretroviral Therapy (ART) Compared to Those Commenced on ART During Pregnancy
  92. Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission
  93. Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis
  94. COVID-19 in Africa: care and protection for frontline healthcare workers
  95. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
  96. Earlier Antiretroviral Therapy Initiation and Decreasing Mortality Among HIV-infected Infants Initiating Antiretroviral Therapy Within 3 Months of Age in South Africa, 2006–2017
  97. The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes—A randomized clinical trial
  98. African Multi-Site 2-Year Neuropsychological Study of School-Age Children Perinatally Infected, Exposed, and Unexposed to Human Immunodeficiency Virus
  99. Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination
  100. Neurodevelopmental delay: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data
  101. Current perspectives on paediatric HIV management from the Mexico International Aids Society Conference, 2019
  102. Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?
  103. Association between caregiver depression symptoms and child executive functioning. Results from an observational study carried out in four sub-Saharan countries
  104. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
  105. Why South Africa urgently needs to support the development of pregnancy exposure registries
  106. What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies
  107. African Multi-Site Two-Year Longitudinal Study of Neurocognition in HIV Infected/Affected Children
  108. 287: Diagnostic accuracy of clinical newborn assessment versus ultrasound to define preterm birth: the PROMISE trial
  109. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP)
  110. Mortality and losses to follow‐up among adolescents living with HIV in the IeDEA global cohort collaboration
  111. Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial
  112. Lamivudine monotherapy as a holding regimen for HIV-positive children
  113. Building capacity in neurodevelopment assessment of children in sub-Saharan Africa: A quality assurance model to implement standardized neurodevelopment testing
  114. HIV retesting in pregnant women in South Africa: Outcomes of a quality improvement project targeting health systems’ weaknesses
  115. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis
  116. High loss to follow-up of children on antiretroviral treatment in a primary care HIV clinic in Johannesburg, South Africa
  117. Validity of Neuropsychological Testing in Young African Children Affected by HIV
  118. Thank you from HMPG and the editors
  119. Lamivudine monotherapy in children and adolescents: The devil is in the detail
  120. Neuropsychological performance in African children with HIV enrolled in a multi-site anti-retroviral clinical trial
  121. Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial
  122. The interaction between equipoise and logistics in clinical trials: A case study
  123. Cutting the cost of South African antiretroviral therapy using newer, safer drugs
  124. Cutting the cost of South African antiretroviral therapy using newer, safer drugs
  125. The Challenge of and Opportunities for Transitioning and Maintaining a Continuum of Care Among Adolescents and Young Adults Living with HIV in Resource Limited Settings
  126. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial
  127. Views of Medical Doctors Regarding the 2013 WHO Adult HIV Treatment Guidelines Indicate Variable Applicability for Routine Patient Monitoring, for Their Family Members and for Themselves, in South-Africa
  128. CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States
  129. Outcomes in treatment with darunavir/ritonavir in ART-experienced paediatric patients
  130. Time to implement 9-month infant HIV testing in South Africa
  131. Outcomes of Infants Starting Antiretroviral Therapy in Southern Africa, 2004–2012
  132. Paradoxical tuberculosis‐associated immune reconstitution inflammatory syndrome in children
  133. HIV and adolescents: focus on young key populations
  134. Providing comprehensive health services for young key populations: needs, barriers and gaps
  135. Virologic Failure Among Children Taking Lopinavir/Ritonavir-containing First-line Antiretroviral Therapy in South Africa
  136. Focus on adolescents with HIV and AIDS
  137. Microbiological investigation for tuberculosis among HIV-infected children in Soweto, South Africa
  138. Evaluation of Parent-Child Pairs on Antiretroviral Therapy in Separate Adult and Pediatric Clinics
  139. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa
  140. Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa
  141. Cost and outcomes of paediatric antiretroviral treatment in South Africa
  142. Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents
  143. Lamivudine Monotherapy as a Holding Strategy in HIV-Infected Children in South Africa
  144. Antiretroviral Therapy Outcomes in HIV-Infected Children after Adjusting Protease Inhibitor Dosing during Tuberculosis Treatment
  145. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study
  146. Lopinavir Exposure is Insufficient in Children Given Double Doses of Lopinavir/Ritonavir during Rifampicin-Based Treatment for Tuberculosis